Compass Therapeutics, Inc. income statement

In fiscal 2025, Compass Therapeutics, Inc. reported revenue of $0, down 100.0% on the year before and net income of −$66.5m. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Compass Therapeutics, Inc.: income statement, annual
Fiscal year	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	0	1	0
Research and development	38	42	56
General and administrative	12	15	17
Operating income	−50	−57	−73
Income before tax	−42	—	—
Income tax	0	0	0
Net income	−42	−49	−66
Diluted shares (average)	127m	137m	158m
EBITDA	−50	−56	−73

US$ millions unless shown otherwise. Fiscal quarters.

Compass Therapeutics, Inc.: income statement, quarterly
Quarter	2023 Q3Sept 2023	2023 Q4Dec 2023	2024 Q2Jun 2024	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025
Revenue	0	0	1	0	0	0	0	0
Research and development	9	12	11	9	13	16	13	14
General and administrative	3	3	5	4	4	5	3	4
Operating income	−12	−15	−15	−12	−17	−21	−16	−18
Income before tax	−10	−13	−13	—	—	—	—	—
Income tax	0	0	0	—	—	—	—	—
Net income	−10	−13	−13	−10	−15	−20	−14	−16
EBITDA	−12	−15	−15	−12	−16	−21	−16	−18

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Compass Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Compass Therapeutics, Inc.